The FDA can’t regulate drug prices, but is making an effort to prevent drug monopolies after Martin Shkreli’s action to hike Daraprim to $750 per pill.

When Turing Pharmaceuticals CEO Martin Shkreli increased the cost of Daraprim, a powerful antiparasitic drug, from $13.50 to $750 per pill, he quickly gained the kind of notoriety usually reserved for comic book villains.

Daraprim was the only drug available to treat toxoplasmosis, a disease caused by Toxoplasma gondii, a parasite that attacks individuals with weakened immune systems. The disease is most commonly seen in patients with AIDS, although it has been found in those undergoing chemotherapy. When left untreated toxoplasmosis is usually fatal.

Shkreli’s smug countenance was plastered about the Internet. The term “pharma bro” entered the cultural lexicon, and the media had a make-a-point-about-the pharmaceutical-industry field day.

Shkreli was referred to as “the face of unapologetic profiteering from the suffering of humans,” “the perfect and very hate-able combination of arrogance, youth, and avarice,” and “the most hated man in America.”

But Johns Hopkins professor of medicine Jeremy Greene, writing for Slate, looked past the immediate outrage, dubbing Shkreli “an unlikely therapeutic reformer.”

Turing exploited a government loophole that allows pharmaceutical companies to charge whatever price they want for drugs with no alternative or generic formulation.

He hasn’t been the only one to use the system to boost drug prices.

On Monday, Reuters posted an exclusive report on price increases on commonly used drugs in the United States over the past five years. The news service revealed that prices on four of the nation’s 10 most widely used drugs jumped more than 100 percent during that period. The other six drugs rose in price by more than 50 percent.

Read More: Why Some Drugs Cost so Much and Others Don’t »